Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease

George H. McCracken, James P. Luby, Stanley A. Plotkin

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Cytosine arabinoside (ARA-C) was used in the treatment of 3 infants with disseminated cytomegalovirus infection. The titer of cytomegalovirus was reduced in vitro 0 to 2 log10 TCID50 with 1.0 μg per millitier, and 2 to 3 log10 TCID50 with 10 and 100 μg per milliliter of ARA-C. The concentration of cytomegalovirus in the urine of the 3 patients was reduced 2 to 3 logs during therapy, but returned to pretreatment titers or higher within several weeks. Transient hematologic and hepatic toxicity were observed during therapy, and ARA-C had no appreciable beneficial effect on the clinical course of the infants.

Original languageEnglish (US)
Pages (from-to)488-495
Number of pages8
JournalThe Journal of pediatrics
Issue number3
StatePublished - Mar 1972

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease'. Together they form a unique fingerprint.

Cite this